MiMedx Group announced it will acquire Sanara MedTech for approximately $350 million in a cash and stock deal, aiming to create a leading regenerative medicine company. The merger will nearly double MiMedx's surgical revenue and expand its product portfolio with Sanara's innovative surgical technologies, including a breakthrough bone fixation device. The combined company expects 2027 revenue to exceed $400 million with over 20% adjusted EBITDA margin, benefiting from $20 million in cost synergies. The deal, approved by both boards, is expected to close by year-end pending shareholder and regulatory approvals.
Intel's stock surged after Northland Securities upgraded it from "Market Perform" to "Outperform" with a $120 price target, following Intel Foundry's progress in High Numerical Aperture Extreme Ultraviolet (High-NA EUV) lithography. Intel has process...
ABM Industries reported strong Q3 2026 results, surpassing analyst EPS estimates with $1.04 per share versus the expected $1.01. The company achieved record revenue of $2.3 billion, a 4.2% increase driven by organic and acquisition growth. Adjusted n...
GameStop is set to report its Q2 2026 earnings with analysts expecting an EPS of $0.27 and revenues around $756.85 million, down from $972.20 million the previous year. The company’s own sales forecast of $780-$800 million confirms a significant reve...
Opus Genetics, a clinical-stage biotech focused on inherited retinal diseases, received a Buy rating and $8 price target from analyst Matthew Caufield in August 2026. The company plans to release topline Phase 1/2 data for its gene therapy OPGx-BEST1...
General Electric (GE) announced it will acquire Consolidated Precision Products (CPP) for $11.75 billion to enhance its aerospace casting production. This strategic move aims to strengthen GE's manufacturing capabilities and accelerate engine technol...
